Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
Information source: National Taiwan University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Renal Failure
Intervention: sustained low efficiency daily hemodiafiltration (SLEDD-f) (Device)
Phase: N/A
Status: Completed
Sponsored by: National Taiwan University Hospital Official(s) and/or principal investigator(s): Fe-Lin L Wu, MSCP, Ph.D., Principal Investigator, Affiliation: School of pharmacy, Graduate institute of clinical pharmacy, Department of Pharmacy of National Taiwan University Hospital, College of Medicine, National Taiwan University Wen-Je Ko, MD, PhD, Principal Investigator, Affiliation: Department of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University
Summary
1. Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal
replacement therapy with high-flux dialyser membrane (helixone).
2. The pore size of helixone is larger than most antibiotics, and vancomycin is supposed
to be removed during dialysis.
3. Our study wants to find the amount of vancomycin removed during SLEDD-f, and try to
find the most appropriate dose regimen for this kind of patients.
Clinical Details
Official title: Pharmacokinetics and Dosing of Vancomycin in Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Primary outcome: The amount of vancomycin removed during one course of SLEDD-fThe pharmacokinetics and dosing regimen of vancomycin in patients on SLEDD-f.
Detailed description:
Vancomycin is the most important antibiotic in the treatment of resistant G(+) bacteria
infections. Close monitor of serum level is important to ensure its safety and
effectiveness. So far there is not enough data to support the optimal dose regimen of
vancomycin in patients on SLEDD-f. In this study, we draw blood levels between 2 doses of
vancomycin to determine the pharmacokinetic parameters of vancomycin and fraction removed by
SLEDD-f so as to determine the most appropriate dose regimen.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Acute renal failure of any cause
- Use SLEDD-f as renal replacement therapy
- Priscribe vancomycin for a known or suspected infection
Exclusion Criteria:
- None
Locations and Contacts
National Taiwan University Hospital, Taipei, Taiwan
Additional Information
Starting date: October 2008
Last updated: October 21, 2009
|